Journal of Pharmacokinetics and Biopharmaceutics, Vol. 20, No. 6, 1992

Author Index to Volume 20

Ambros, Reinhard J., 421

Barfknecht, Charles F., 357
Berner, Bret, 443
Burke, Martin, 559
Burnette, Ronald R., 477

Davidian, Marie, 531
Dedrick, Robert L., 95
Dewitte, Wayne, 443
Diaz-Garcia, Juan M., 171
Diletti, Edgar, 559
Donoho, David, L., 63
du Souich, Patrick, 461

Endrenyi, Laszlo, 279
Evans, Allan M., 171

Fisher, Lynn E., 319
Fung, Ho-Leung, 227

Gallant, A. Ronald, 531
Grasela, Thaddeus H., 295, 393
Gregg, Keith M., 147
Guillard, Stephanie, 195

Hallak, Hussein O., 1
Haughey, David B., 333
Hauschke, Dieter, 559
Holford, Nicholas H. G., 421

Jusko, William J., 319, 333

King, Franklin G., 95
Kochak, Gregory M., 443

Laban, Saad L., 357
Leal, Marion, 443
Lee, Ping I., 105
Liu, Dong Y., 295
Ludwig, Elizabeth A., 319

Mandema, Jaap W., 511
Modi, Nishit B., 397

Ong, Huy, 461

Pang, K. Sandy, 105, 253
Perreault, Sylvie, 461
Phillips, Kem F., 380
Pond, Susan M., 19
Purves, Robert D., 211, 501

Rao, Chakradhara S., 357
Rivory, Laurent P., 19
Roberts, Michael S., 19
Rodriguez, Carlos A., 195
Rowland, Malcolm, 171

Sambol, Nancy, 443
Schoenwald, Ronald D., 357
Shafer, Steven L., 63, 147
Sheiner, Lewis B., 511
Siegel, Ronald A., 413
Smith, David E., 195
St-Pierre, Marie V., 105
Steinijans, Volker W., 559
Stoeckel, Klaus, 421

Tung, Ying, 393
Tzeng, Tsang-Bin, 227

Varvel, John R., 63
Veng-Pedersen, 397
Verotta, Davide, 511

Walawander, Cynthia A., 295, 393
Wedlund, Peter J., 1
Weiss, Michael, 253
Weng, Jenny, 279
White, Donald B., 295, 393

0090-466X/92/1200-0673$06.50/0 © 1992 Plenum Publishing Corporation

Journal of Pharmacokinetics and Biopharmaceutics, Vol. 20, No. 6, 1992

Subject Index to Volume 20

Absorption models, 421
Alkylphenylpropionic (or acetic), 358
Anesthesia, 63
Area-under-the-curve, 211, 501
Axial tissue diffusion, 19
Bioavailability, 421
Bioequivalence, 559

Cefetamet, 421
Cell trafficking, 333
Chlorothiazide, 195
Chronopharmacokinetics, 477
Chronopharmacology, 333
Circadian rhythm, 477
Circulation time distribution, 253
Cis-dichlorodiammine-platinum, 95
Cisplatin, 95
Clinical trials, 295
Computational efficiency, 279
Computer driven, 147
Computer simulation, 279
Computer-assisted equipment, 63
Computers, 147
Confidence intervals, 295
Curve moments, 253

Density estimation, 531
Diazepam, 171
Dispersion model, 19, 107, 171
Distributed-tube model, 19
Drug delivery, 147
Drug disposition curve, 253
Dynamics, 461
Dynamics of drug distribution, 253

Effect site, 147
Enzyme heterogeneity, 19
Experimental design, 279

First pass effect, 461
Fixed effect variance, 443
Flow dependence, 1
Flow heterogeneity, 19

Generalized additive models, 511

Helper T lymphocytes, 333
Hepatic availability, 19
Hepatic blood flow, 19
Hepatic clearance, 107
Hepatic elimination, 19, 171
Hypothesis testing, 295

Immunosuppression, 333
Infusion pump, 63
Infusions, 147
Isolated perfused rat liver, 171
Isomeric organic mononitrates, 211

Large-sampled method, 279
Likelihood ratio test, 295
Linear systems analysis, 477
Lipophilic drugs, 19

Maximum likelihood, 531
Metabolite formation and elimination, 107
Metabolite kinetics, 19
Methylprednisolone, 333
Mixing curve, 253
MKMODEL, 421
Model building, 511
Moment analysis, 501
Monoexponential model, 295
Multiplicative model, 559

Nitroglycerin, 443
Non-compartmental analysis, 253, 211, 501
Noneliminating and eliminating system, 253
Nonlinear mixed effects models, 531
NONMEM, 279, 295, 421, 511
Nonparametric estimation, 531
Nonsteroidal antiinflammatory agents, 358
Numerical integration, 211

Ocular pharmacokinetics, 358

Parallel-tube model, 19, 107
Parameter estimation, 279

0090-466X/92/1200-0675$06.50/0 © 1992 Plenum Publishing Corporation

Perfusion flow rate, 195
Pharmacodynamic modeling, 211
Pharmacodynamics, 147, 333
Pharmacokinetic modeling, 1
Pharmacokinetic models, 477
Pharmacokinetics, 95, 147, 511
Physiological model, 95, 171
Population analysis, 511
Population pharmacokinetics, 279, 295, 421, 531
Power, 295, 559
Predictive performance, 63
Primary, secondary and tertiary metabolites, 107
Protein binding, 19, 171

Quinidine, 531

Rabbits, 358
Random intersubject and intrasubject variance, 443
Rat IPK, 195
Recirculation model, 253
Residence time distribution, 253
Reversible metabolism, 1
Route of administration, 461

Salbutamol, 461
Sample size, 559
Sequential elimination, 107
Simulations, 295
Skewing, 253
Surface activity, 358

Tail correction, 501
Transdermal delivery, 443

Variance, 253
Variational stability, 443
Vasodilating potencies, 211
Vitamin K, 1
Vitamin K epoxide, 1

Warfarin, 1
Well-stirred model, 19, 107